Essentials of Cardiopulmonary Physical Therapy
1. Introduction - p. 259 2. Obesity - p. 259 3. Diabetes mellitus - p. 271 4. Clinical implications for physical therapy - p. 277 5. Chronic kidney disease and failure - p. 281 6. Other specific diseases and disorders - p. 286 7. Cardiopulmonary toxicity of cancer treatment - p. 295 8. Summary - p. 298 9. Section 3. Diagnostic Tests and Procedures - p. 307 10. 10. Cardiovascular diagnostic tests and procedures - p. 307 11. Diagnostic test interpretation and probability of disease - p. 309 12. Sensitivity/specificity of testing - p. 309 13. Clinical laboratory studies - p. 309 14. Other noninvasive diagnostic tests - p. 317 15. Other imaging modalities - p. 320 16. Exercise testing - p. 321 17. Pharmacologic stress testing - p. 330 18. Cardiac catheterization: coronary angiography and ventriculography - p. 334 19. Digital subtraction angiography - p. 336 20. Endocardial biopsy - p. 337 21. Vascular diagnostic testing for aortic, peripheral, and carotid disease - p. 337 22. Peripheral arterial disease and dysfunction and diagnosis - p. 337 23. Carotid artery disease and diagnosis - p. 341 24. Summary - p. 342 25. 11. Electrocardiography - p. 347 26. 12. Pulmonary diagnostic tests and procedures - p. 380.e1 27. Section 4. Surgical Interventions, Monitoring, and Support - p. 407 28. 13. Cardiovascular and thoracic interventions - p. 407 29. 14. Thoracic organ transplantation heart and lung - p. 435.e1 30. 15. Monitoring, life support devices, and respiratory care in intensive care unit - p. 468 31. Monitoring equipment in the intensive care unit - p. 468 32. Capnography - p. 471 33. Invasive monitoring - p. 475 34. Temperature monitoring - p. 481 35. Intracranial pressure monitoring - p. 482 36. Life support equipment - p. 482 37. Summary - p. 509 38. Section 5. Pharmacology - p. 513 39. 16. Cardiovascular medications - p. 513 40. Pharmacokinetics - p. 515 41. Pharmacodynamics - p. 517 42. General considerations of pharmacologic management - p. 518 43. Cardiac drugs used in critical care - p. 547 44. Cardiac pharmacology in the geriatric population - p. 551 45. Cardiac pharmacology in the neonate and pediatric populations - p. 552 46. Pharmacologic management of diabetes - p. 553 47. Heart transplantation - p. 556 48. Vascular pharmacology - p. 558 49. Summary - p. 560 50. 17. Pulmonary medications - p. 564.e1 51. Section 6. Cardiopulmonary Assessment and Intervention - p. 585.e1 52. 18. Examination and assessment procedures - p. 585.e1 53. 19. Interventions for acute cardiopulmonary conditions - p. 620.e1 54. 20. Interventions and prevention measures for individuals with cardiovascular disease, or risk of disease - p. 654.e1 55. Introduction - p. 654.e1 56. Primary prevention - p. 656 57. Rehabilitation of patients with documented cardiovascular disease - p. 658 58. Management and evaluation of patients during the acute phase - p. 660 59. Postacute phase rehabilitation - p. 667 60. Candidacy - p. 667 61. Home-based cardiac rehabilitation - p. 667 62. Rehabilitation/secondary prevention in the outpatient setting - p. 668 63. Secondary prevention: management of risk factors - p. 678 64. Administrative considerations - p. 689 65. Summary - p. 693 66. 21. Pulmonary rehabilitation - p. 696.e4 67. 22. Pediatric cardiopulmonary physical therapy - p. 721 68. 23. Outcome measures: A guide for the evidence-based practice of cardiopulmonary physical therapy - p. 747 69. 24. The lymphatic system - p. 778 70. Glossary - p. 804.e1 71. Index - p. e35
Essentials of Cardiopulmonary Physical Therapy
1. Introduction - p. 259 2. Obesity - p. 259 3. Diabetes mellitus - p. 271 4. Clinical implications for physical therapy - p. 277 5. Chronic kidney disease and failure - p. 281 6. Other specific diseases and disorders - p. 286 7. Cardiopulmonary toxicity of cancer treatment - p. 295 8. Summary - p. 298 9. Section 3. Diagnostic Tests and Procedures - p. 307 10. 10. Cardiovascular diagnostic tests and procedures - p. 307 11. Diagnostic test interpretation and probability of disease - p. 309 12. Sensitivity/specificity of testing - p. 309 13. Clinical laboratory studies - p. 309 14. Other noninvasive diagnostic tests - p. 317 15. Other imaging modalities - p. 320 16. Exercise testing - p. 321 17. Pharmacologic stress testing - p. 330 18. Cardiac catheterization: coronary angiography and ventriculography - p. 334 19. Digital subtraction angiography - p. 336 20. Endocardial biopsy - p. 337 21. Vascular diagnostic testing for aortic, peripheral, and carotid disease - p. 337 22. Peripheral arterial disease and dysfunction and diagnosis - p. 337 23. Carotid artery disease and diagnosis - p. 341 24. Summary - p. 342 25. 11. Electrocardiography - p. 347 26. 12. Pulmonary diagnostic tests and procedures - p. 380.e1 27. Section 4. Surgical Interventions, Monitoring, and Support - p. 407 28. 13. Cardiovascular and thoracic interventions - p. 407 29. 14. Thoracic organ transplantation heart and lung - p. 435.e1 30. 15. Monitoring, life support devices, and respiratory care in intensive care unit - p. 468 31. Monitoring equipment in the intensive care unit - p. 468 32. Capnography - p. 471 33. Invasive monitoring - p. 475 34. Temperature monitoring - p. 481 35. Intracranial pressure monitoring - p. 482 36. Life support equipment - p. 482 37. Summary - p. 509 38. Section 5. Pharmacology - p. 513 39. 16. Cardiovascular medications - p. 513 40. Pharmacokinetics - p. 515 41. Pharmacodynamics - p. 517 42. General considerations of pharmacologic management - p. 518 43. Cardiac drugs used in critical care - p. 547 44. Cardiac pharmacology in the geriatric population - p. 551 45. Cardiac pharmacology in the neonate and pediatric populations - p. 552 46. Pharmacologic management of diabetes - p. 553 47. Heart transplantation - p. 556 48. Vascular pharmacology - p. 558 49. Summary - p. 560 50. 17. Pulmonary medications - p. 564.e1 51. Section 6. Cardiopulmonary Assessment and Intervention - p. 585.e1 52. 18. Examination and assessment procedures - p. 585.e1 53. 19. Interventions for acute cardiopulmonary conditions - p. 620.e1 54. 20. Interventions and prevention measures for individuals with cardiovascular disease, or risk of disease - p. 654.e1 55. Introduction - p. 654.e1 56. Primary prevention - p. 656 57. Rehabilitation of patients with documented cardiovascular disease - p. 658 58. Management and evaluation of patients during the acute phase - p. 660 59. Postacute phase rehabilitation - p. 667 60. Candidacy - p. 667 61. Home-based cardiac rehabilitation - p. 667 62. Rehabilitation/secondary prevention in the outpatient setting - p. 668 63. Secondary prevention: management of risk factors - p. 678 64. Administrative considerations - p. 689 65. Summary - p. 693 66. 21. Pulmonary rehabilitation - p. 696.e4 67. 22. Pediatric cardiopulmonary physical therapy - p. 721 68. 23. Outcome measures: A guide for the evidence-based practice of cardiopulmonary physical therapy - p. 747 69. 24. The lymphatic system - p. 778 70. Glossary - p. 804.e1 71. Index - p. e35
